Danaher Is Cheaper Than You Think, And Everyone's Focused On The Wrong Thing

# Danaher Is Cheaper Than You Think, And Everyone's Focused On The Wrong Thing

Let's get the noise out of the way first, because it's loud and it's mostly about a party leaving the building.

On October 1st, Danaher handed the CEO keys to Julie Sawyer Montgomery. The stock, ever the dramatic lover, fell roughly 4% intraday and closed down 4.5% at $211.71. Former boss Rainer Blair didn't vanish—he's staying on as a senior advisor until March 2027—but Wall Street's instinct is to sell the transition and buy the mystery later. So here we are: DHR around $214, down about 6–8% year-to-date, sitting roughly 11% under its 52-week high of $242.80.

The market told you this is a story about leadership risk. I think it's a story about a premium multiple with the paint still drying.

Here's what actually bugs me about this name. Danaher reported Q2 earnings in late July and beat on both the top and bottom line—revenue of $6.26 billion against a $6.12 billion estimate, EPS of $1.94 versus $1.85 expected. It even raised full-year guidance. And yet the stock got punished, because Q2 operating margin collapsed to 18% from 22.6% in the prior quarter. That's a nine-point hole in one print, and numbers like that make disciplined investors reach for the exit button.

But margins are what they are when you're in the middle of a bioprocessing destocking cycle. Danaher's own people told clients bioprocessing equipment orders were actually accelerating—high single-digit growth in the segment, 30%-plus in equipment orders, flowing through Cytiva and Pall. The problem was clients deferring roughly $100 million in bioprocessing equipment into 2027, and the acquisition integration dragging. That's not a broken business. That's a business going through a rough quarter and telling you the trough might be closer than the tape assumes.

Now the valuation, which is where I think the bears are asleep at the wheel. DHR trades near 38x trailing earnings and about 25x forward. On a normal day, that's a number you sneer at. But you're paying that for a company with a fortress balance sheet—$4.35 billion in cash, a 0.53x debt-to-equity ratio, $5.28 billion in working capital—and generating roughly $1.27 billion in free cash flow every single quarter. That cash engine funds maybe $3 billion in annual buybacks. This is not a company burning money to look interesting. It's a company compounding through a cycle and getting railed for doing it.

Let me be clear about what's happening with the analysts, because it matters. Goldman Sachs, back on September 21st, raised its target from $210 to $250 and held a Buy. Guggenheim matched it at $250. The median consensus sits around $230 to $233, with a range that runs from a pessimistic $195 to a giddy $310. Nobody's calling for a fire sale; they're calling for the stock to be worth more than it is.

So what's the actual setup?

There's one event that dominates everything, and it's not the CEO handover. That already happened and the tape absorbed it. The event is October 21st—Q3 earnings, before the bell, with a conference call at 8 a.m. ET. Consensus is sitting at about $1.96 in EPS and $6.55 billion in revenue. Danaher has beaten in all four of its recent quarters, so the bar isn't impossibly high. But the single thing that will decide whether this stock re-rates or re-compresses is the margin trajectory. Did the 18% print stabilize? Did bioprocessing show any sign of turning?

Here's my honest read: I'd be a fool to size into a binary earnings print blind. This isn't a swing trade you cherry-pick on faith. The constructive play is to respect the tape. DHR has reclaimed its 50-day and 200-day moving averages after a trough near $170 in late September, and it's bouncing constructively. Resistance is the $220 zone and then that $242.80 high. Support is the 50-day around $209, then $200, then the $196 lows. If you want to own this name, accumulating on tests of $200 with a stop under $196 is a far more honest entry than buying the chop and hoping October 21st saves you.

The reason I'm not piling onto the sell side is simple. You have a $150 billion healthcare compounder, mid-cycle margin compression that's explainable, a CEO transition that was a clean internal promotion not a crisis, Goldman buying the dip to $250, and an earnings catalyst two weeks out that could flip the entire narrative. The downside is real and it's called valuation compression—you're still paying a rich multiple for growth that was barely mid-single-digits. But the asymmetry here, into a print that could confirm a margin floor, is genuinely interesting.

The crowd is still snifing at the departing CEO. The smarter money is looking at October 21st and wondering why everyone forgot what this business does when the cycle turns. I'll be watching the margins, not the exit interview.